UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area
code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. | Other Events. |
Tonix Pharmaceuticals Holding Corp. (the “Company”) is filing this Current Report on Form 8-K to include, as Exhibit 23.1, the consent of KPMG LLP to be incorporated by reference in the Company’s Registration Statement on Form S-3 (File No. 333-254975).
Item 9.01 | Financial Statements and Exhibits. |
(d) |
Exhibit No. |
Description. | ||
Consent of KPMG LLP | ||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
TONIX PHARMACEUTICALS HOLDING CORP. | |||
Date: July 27, 2023 | By: | /s/ Bradley Saenger | |
Bradley Saenger | |||
Chief Financial Officer |
TONIX PHARMACEUTICALS HOLDING CORP. 8-K
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the registration statement (No. 333-254975) on Form S-3 of Tonix Pharmaceuticals Holding Corp. of our report dated July 18, 2023, with respect to the abbreviated financial statements of the Tosymra® and Zembrace® Symtouch® Product Lines of Upsher-Smith Laboratories, LLC, not included herein, which report appears in the Form 8-K/A dated July 18, 2023 of Tonix Pharmaceuticals Holding Corp. and to the references to our firm under the heading of “Experts” in the prospectus supplement contained in such registration statement.
/s/ KPMG LLP |
Minneapolis, Minnesota
July 25, 2023
Cover |
Jul. 27, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jul. 27, 2023 |
Entity File Number | 001-36019 |
Entity Registrant Name | TONIX PHARMACEUTICALS HOLDING CORP. |
Entity Central Index Key | 0001430306 |
Entity Tax Identification Number | 26-1434750 |
Entity Incorporation, State or Country Code | NV |
Entity Address, Address Line One | 26 Main Street |
Entity Address, City or Town | Chatham |
Entity Address, State or Province | NJ |
Entity Address, Postal Zip Code | 07928 |
City Area Code | (862) |
Local Phone Number | 904-8182 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock |
Trading Symbol | TNXP |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
"6)53#);V':Y&0M%'<:, -56SBH"*JRE(O(6K*
MTBXT'70AB\4?7!?>,\JC+EQGG+IC,J7@NGT_8G?/]'IPSR(36]_--\Z2C,7D
M:O8WQ45I>A (%5'E&B&[\"LGX6=H(UPM.(L>%P-AC$C*]5:Y[O3WTD#+GN^A
M_?[\NX+36P*Z.D0"L:*3$\>D#_*OX\]N\ZA]U.[L(_%.__;J\OP/&)\-KB\&
MP]-/M^?#P>@&SJY&[\XO/\#PZGJ\#\?N1]\C"ZKJG)1(GXH8^F! B/AU*\_8B:#[
M7BA:2M=< %9-- Q94'38O8& 5'*_C"P%9FFB!K!>2-I2YZ<;@-G6J8>A"XH3
MP!Q\2E+I_9*R>"24JOL!F/4/*#:Q:UI@PR8O;650Q(#V0&;R"%2&A(/-Y8M:
MG+BTO/7!H@+4>D:%^,0D7UC=BCO!
M7Q(6P4MF2.X%&,"TE1I#&QXZ=H-]_%0+8AWG=:PI%N6]7Q(M\S/*-$W:AYA"
M$QXD36.]@TNA]HG$'4\S3/^=/'>>B-O%7O"P&K9"TE"&AXK-7A\P10R203Y.
MK$M9R=]A:OT+/C0(EH.&!G,3)T XTEV0_K'1BR;7ZP
*IT@\'&@ 7XMZJ#$&=ED(XE:S5=Q=,+/+N)0QQ*)N*)>'H3N#D?W.((ZRK\
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M7E?,I?KT].DY45E+GV +)QZ"Q2KET$-; X>(XN%HK/Q6:"3 UUF0J8RBV[
M(MNX,&?!@S1O6QH&ZELQR&M9)"M @/?0%6-0MF.=.((%#UF2Y@C+=&SA@NM*
M>>CC ?.:@B@8M!7P';]K&R#V:51V+